Vitamin B12 Deficiency: Causes, Symptoms, and How to Fix It

The absorption of vitamin B12 from food is one of the most elaborate nutrient uptake processes in human physiology, involving multiple proteins and occurring in two distinct phases. Dietary B12 in food is bound to proteins; acid and pepsin in the stomach release it, after which it binds to haptocorrin (also called R-protein) secreted in saliva. In the small intestine, pancreatic proteases degrade haptocorrin, releasing B12 to bind to intrinsic factor — a glycoprotein produced by parietal cells in the stomach lining. The B12-intrinsic factor complex then travels to the terminal ileum, where it binds to cubilin receptors on intestinal cells and is absorbed. This elegant system has numerous potential failure points. Autoimmune destruction of parietal cells causes atrophic gastritis, reducing intrinsic factor production and gastric acid secretion; this is the basis of pernicious anaemia, the classic and most severe cause of B12 deficiency in non-dietary groups. Proton pump inhibitors (PPIs) and H2 blockers used to treat acid reflux significantly reduce gastric acid, impairing the initial release of B12 from food protein and potentially causing clinically significant deficiency with long-term use. Metformin, widely prescribed for type 2 diabetes, reduces B12 absorption by inhibiting calcium-dependent cubilin expression in the ileum. Surgical removal of the stomach or terminal ileum eliminates intrinsic factor or absorption sites respectively. Bacterial overgrowth in the small intestine can consume B12 before absorption occurs. Notably, large doses of supplemental B12 (above 500mcg) bypass intrinsic factor through passive diffusion across the gut wall, making high-dose oral supplementation effective even in pernicious anaemia.

The clinical presentation of B12 deficiency is dominated by two systems: haematological and neurological. On the blood side, B12 deficiency causes megaloblastic anaemia — characterised by abnormally large but poorly functional red blood cells — with symptoms of fatigue, weakness, shortness of breath on exertion, pallor, and heart palpitations. Elevated mean corpuscular volume (MCV) on a full blood count is often the first laboratory clue. On the neurological side, deficiency causes subacute combined degeneration of the spinal cord — a demyelinating process affecting the dorsal and lateral columns — with symptoms that begin with peripheral neuropathy: tingling, numbness, burning, or pins-and-needles sensations in the hands and feet. As damage progresses, patients may develop balance and coordination problems, difficulty walking, muscle weakness, and in severe cases spastic paralysis. Cognitive symptoms — memory loss, confusion, difficulty concentrating, and in severe cases dementia — are particularly concerning because they may be misattributed to ageing or primary psychiatric conditions. Depression, irritability, and personality changes are also documented. A critical clinical point is that neurological damage can occur with minimal anaemia, particularly in people who have high folate intake (which masks the haematological manifestations while allowing neurological damage to progress). Elevated homocysteine — a cardiovascular risk factor — is an early sensitive marker of B12 insufficiency, as is elevated methylmalonic acid (MMA), which rises when the second B12-dependent enzyme fails. Both are more sensitive markers of functional deficiency than serum B12 alone.

Certain groups face substantially elevated risk of B12 deficiency and deserve regular screening and proactive nutritional attention. Vegans are perhaps the most high-profile at-risk group: since B12 is found naturally only in animal foods (meat, fish, dairy, eggs), those eating exclusively plant-based diets will develop deficiency without supplementation or consumption of B12-fortified foods. This is not a matter of debate — it is a biochemical certainty over time, since the body's B12 stores (primarily in the liver) can sustain normal function for 2–5 years after dietary intake ceases but will eventually be exhausted. Vegetarians who consume dairy and eggs have lower risk but are still more likely to be insufficient than omnivores. Older adults represent the other major at-risk group: the prevalence of atrophic gastritis — with consequent reduced acid and intrinsic factor secretion — increases markedly with age, affecting an estimated 10–30% of people over 60. Many elderly people with B12 deficiency can absorb high-dose oral supplements despite impaired intrinsic factor production because passive diffusion is sufficient at doses above 500mcg. Long-term users of metformin or PPIs require monitoring. People with Crohn's disease affecting the terminal ileum, those who have undergone gastric surgery or bypass, and those with coeliac disease or other malabsorptive conditions are at elevated risk. Pregnancy and breastfeeding increase B12 requirements, and B12 status is critical for foetal neurological development. Exclusively breastfed infants of vegan mothers are at high risk of severe deficiency and require supplementation.

Vitamin B12 is found naturally only in foods of animal origin, with organ meats topping the list by a considerable margin. A 75g serving of beef liver provides an extraordinary 70mcg of B12 — hundreds of times the recommended daily intake of 2.4mcg — reflecting the liver's role as the primary B12 storage organ. Clams, mussels, oysters, and other shellfish are similarly concentrated, with a 85g serving of clams providing around 84mcg. Mackerel, sardines, herring, and trout each provide 7–12mcg per 100g serving. Beef provides approximately 2.6mcg per 100g, pork and chicken around 0.5–0.9mcg. Dairy products contribute usefully to intake: a 240ml glass of cow's milk contains roughly 1.2mcg, cheddar cheese provides around 0.8mcg per 30g, and plain yoghurt around 1.0mcg per 170g. Eggs provide about 0.6mcg per large egg, concentrated in the yolk. For people who avoid animal products, fortified foods are the primary dietary source. Many plant milks, breakfast cereals, nutritional yeast, and vegan meat alternatives are now fortified with B12, typically as cyanocobalamin or methylcobalamin. Nutritional yeast can be particularly useful if regularly fortified at meaningful levels — check labels, as B12 content varies considerably between brands. Fermented plant foods, algae such as spirulina, and soil-grown vegetables are sometimes cited as plant-based B12 sources, but the forms they contain are largely biologically inactive analogues that may actually interfere with genuine B12 metabolism.

Diagnosing B12 deficiency accurately is more nuanced than a single blood test might suggest. Standard serum vitamin B12 tests measure total circulating cobalamin, but this includes inactive B12 analogues bound to haptocorrin, which have no biological function. The test can therefore report normal-range values in people who are functionally deficient at the cellular level. The generally accepted lower reference range of 200–300 pg/mL is now considered by many specialists to be too low — studies show neurological symptoms can occur at levels that standard laboratories report as normal. More reliable functional markers include serum methylmalonic acid (MMA), which accumulates when the second B12-dependent enzyme methylmalonyl-CoA mutase is impaired, and total homocysteine, which rises when methionine synthase activity falls. Both are elevated in functional B12 deficiency before serum B12 itself falls below the lower limit. Holotranscobalamin — the metabolically active fraction of circulating B12 bound to transcobalamin II — is a newer and arguably the most sensitive early marker, now available in some specialist laboratories. If pernicious anaemia is suspected, intrinsic factor antibodies and parietal cell antibodies can be measured. For clinical practice, a serum B12 below 300 pg/mL in the presence of relevant symptoms, elevated MMA, or elevated homocysteine is generally considered sufficient evidence to begin treatment, particularly given the low risk of B12 supplementation and the potentially serious consequences of under-treatment.

The traditional treatment for B12 deficiency due to malabsorption — including pernicious anaemia — is intramuscular injection, which bypasses the need for gastric acid and intrinsic factor entirely. Standard injection regimens typically involve loading doses (1000mcg daily or alternate-day for 1–2 weeks) followed by maintenance injections every 3 months. However, research published over the past two decades has convincingly demonstrated that high-dose oral supplementation (1000–2000mcg daily) is equally effective at restoring B12 status and reversing deficiency, even in people with pernicious anaemia, because approximately 1% of any oral dose is absorbed by passive diffusion regardless of intrinsic factor status. At 1000mcg oral dose, this passive absorption equates to approximately 10mcg — well above the 2.4mcg daily requirement. Some patients nonetheless prefer injections for certainty of absorption, to avoid pill burden, or because they experience better symptom control. For dietary deficiency in vegans and vegetarians, a daily oral supplement of 250–1000mcg or a weekly dose of 2000mcg of cyanocobalamin is recommended by most plant-based nutrition authorities. Methylcobalamin is a popular alternative as it is the active coenzyme form, though evidence for superior clinical efficacy over cyanocobalamin is mixed. Sublingual B12 supplements are marketed as better absorbed but evidence does not support a significant advantage over swallowed oral tablets. For infants and young children of vegan mothers, immediate supplementation is critical given the severity of B12 deficiency consequences during neurodevelopment.